• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于充分病因模型的效应度量。2. 与单一预防因素相关的疾病风险和发病率。

Measures of effect based on the sufficient causes model. 2. Risks and rates of disease associated with a single preventive agent.

作者信息

Allard R, Boivin J F

机构信息

Department of Preventive Medicine, Saint-Luc Hospital, Montreal, Quebec, Canada.

出版信息

Epidemiology. 1993 Nov;4(6):517-23. doi: 10.1097/00001648-199311000-00007.

DOI:10.1097/00001648-199311000-00007
PMID:8268280
Abstract

We considered a simple formulation of the sufficient causes model, in which a preventive agent exerts its effect by preventing a sufficient cause of the disease from occurring, while leaving another sufficient cause unaffected. In a group unexposed to the preventive agent, a case of the disease is caused by whichever of the two sufficient causes occurs alone or first in the subject. Among exposed subjects, the preventive agent prevents only the cases of disease in which the sufficient cause it blocks would have occurred alone, not the cases in which the other sufficient cause also occurs during the study period. The proportion of subjects who would avoid the disease if exposed to the preventive agent is the risk difference. The risk difference varies over time, even when the rates of occurrence of the sufficient causes are constant. It increases to a maximum and then declines, as the subjects who have avoided the disease because of the agent later contract the same disease because of exposure to the other sufficient cause. This maximum and the time at which it occurs are readily computed from the incidence rates of disease among exposed and unexposed subjects.

摘要

我们考虑了充分病因模型的一种简单形式,其中预防剂通过阻止疾病的充分病因发生来发挥作用,而另一个充分病因不受影响。在未接触预防剂的人群中,疾病病例是由两个充分病因中单独出现或在个体中首先出现的任何一个病因引起的。在接触预防剂的人群中,预防剂仅预防那些其阻止的充分病因本会单独发生的疾病病例,而不预防在研究期间另一个充分病因也出现的病例。如果接触预防剂就会避免患该疾病的人群比例就是风险差。风险差会随时间变化,即使充分病因的发生率保持不变。它会先增加到最大值然后下降,因为因该预防剂而避免患病的个体后来会因接触另一个充分病因而患上相同疾病。这个最大值及其出现的时间可以根据接触和未接触预防剂人群中的疾病发病率轻松计算出来。

相似文献

1
Measures of effect based on the sufficient causes model. 2. Risks and rates of disease associated with a single preventive agent.基于充分病因模型的效应度量。2. 与单一预防因素相关的疾病风险和发病率。
Epidemiology. 1993 Nov;4(6):517-23. doi: 10.1097/00001648-199311000-00007.
2
Measures of effect based on the sufficient causes model. 1. Risks and rates of disease associated with a single causative agent.
Epidemiology. 1993 Jan;4(1):37-42. doi: 10.1097/00001648-199301000-00008.
3
Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group.
AIDS. 1994 May;8(5):625-34. doi: 10.1097/00002030-199405000-00008.
4
The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.齐多夫定单独使用或与阿昔洛韦联合治疗艾滋病及艾滋病相关综合征患者的疗效和安全性:一项双盲随机试验。欧洲-澳大利亚协作组
AIDS. 1993 Feb;7(2):197-207. doi: 10.1097/00002030-199302000-00007.
5
Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.接受齐多夫定治疗的晚期人类免疫缺陷病毒病患者鸟分枝杆菌复合群感染的发病率和自然史。齐多夫定流行病学研究组。
Am Rev Respir Dis. 1992 Aug;146(2):285-9. doi: 10.1164/ajrccm/146.2.285.
6
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.齐多夫定(AZT)治疗轻度症状的1型人类免疫缺陷病毒(HIV)感染患者的安全性和有效性。一项双盲、安慰剂对照试验。艾滋病临床试验组。
Ann Intern Med. 1990 May 15;112(10):727-37. doi: 10.7326/0003-4819-112-10-727.
7
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.齐多夫定用于无症状人类免疫缺陷病毒感染。对每立方毫米CD4阳性细胞少于500个的患者进行的对照试验。美国国立过敏与传染病研究所艾滋病临床试验组。
N Engl J Med. 1990 Apr 5;322(14):941-9. doi: 10.1056/NEJM199004053221401.
8
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).对有艾滋病进展高风险的无症状HIV感染受试者每日两次服用齐多夫定:一项随机、双盲、安慰剂对照研究。欧洲-澳大利亚协作组(研究017)
AIDS. 1994 Mar;8(3):313-21. doi: 10.1097/00002030-199403000-00004.
9
Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.协和研究:医学研究委员会/法国国家艾滋病研究机构关于在无症状HIV感染中使用齐多夫定立即治疗和延迟治疗的随机双盲对照试验。协和研究协调委员会
Lancet. 1994 Apr 9;343(8902):871-81.
10
Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.接受齐多夫定治疗的晚期艾滋病患者的自然病史。齐多夫定流行病学研究组。
AIDS. 1992 Jul;6(7):671-7.

引用本文的文献

1
Assessing causal mechanistic interactions: a peril ratio index of synergy based on multiplicativity.评估因果机制相互作用:基于可加性的协同增效危险比指数。
PLoS One. 2013 Jun 24;8(6):e67424. doi: 10.1371/journal.pone.0067424. Print 2013.